Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Volume 13(Suppl 1);  2011

Introduction

Anti-TNF therapy: what have we learned in 12 years?
Joachim R Kalden
Arthritis Res Ther. 2011; 13(Suppl 1): S1. Published online 2011 May 25. doi: 10.1186/1478-6354-13-S1-S1
PMCID:
PMC3123962
Article PDF–115K

Reviews

Infliximab: 12 years of experience
Josef S Smolen, Paul Emery
Arthritis Res Ther. 2011; 13(Suppl 1): S2. Published online 2011 May 25. doi: 10.1186/1478-6354-13-S1-S2
PMCID:
PMC3123963
Abstract Article PDF–761K
Understanding emerging treatment paradigms in rheumatoid arthritis
Ferdinand C Breedveld, Bernard Combe
Arthritis Res Ther. 2011; 13(Suppl 1): S3. Published online 2011 May 25. doi: 10.1186/1478-6354-13-S1-S3
PMCID:
PMC3123964
Abstract Article PDF–545K
Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future
Georg Schett, Laura C Coates, Zoe R Ash, Stefanie Finzel, Phillip G Conaghan
Arthritis Res Ther. 2011; 13(Suppl 1): S4. Published online 2011 May 25. doi: 10.1186/1478-6354-13-S1-S4
PMCID:
PMC3123965
Abstract Article PDF–183K
Advances in rheumatology: new targeted therapeutics
Paul P Tak, Joachim R Kalden
Arthritis Res Ther. 2011; 13(Suppl 1): S5. Published online 2011 May 25. doi: 10.1186/1478-6354-13-S1-S5
PMCID:
PMC3123966
Abstract Article PDF–327K
Articles from Arthritis Research & Therapy are provided here courtesy of BMC
-